Lipocine is trading 5.35% up at $2.27, supported mainly by broader biotech-sector strength.
- Biotech ETF XBI is up 2.06% during the regular session, providing an industry tailwind.
- Lipocine’s latest identified corporate update was its August 4, 2026 second-quarter release.
- That filing did not identify an August 26 catalyst or announcement.